**Patient**: Harold Jenkins (DOB 1956-11-24)  
**MRN**: 629541  
**Admission**: 2025-03-22 | **Discharge**: 2025-03-30  
**Physicians**: Dr. N. Rivera (Gastroenterology), Dr. S. Chen (Medical Oncology), Dr. J. Wilson (Interventional Radiology)

**Discharge diagnosis: Acute cholangitis in PDAC**

**1. Oncological Diagnosis**

* **Primary**: Pancreatic Ductal Adenocarcinoma, head of pancreas (Diagnosed 2025-02-10)
* **Stage**: T4N1M1 (Stage III), locally advanced/unresectable
* **Pathology**: Moderately differentiated PDAC; IHC: CK7+, CK20-, CA19-9+, CDX2-, MUC1+
* **Molecular**: KRAS G12D, CDKN2A loss, TP53 mutation
* **Tumor size**: 3.6 × 3.2 cm, encasing SMA (>180°), abutting portal vein
* **Lymph nodes**: Enlarged peripancreatic (largest 1.5 cm)
* **Tumor markers**: CA 19-9: 2,450 U/mL, CEA: 15.8 ng/mL

**2. Current Admission**

* **Presentation**: Cholangitis with fever (39.1°C), RUQ pain, jaundice
* **Imaging**: CBD 14 mm with intra- and extrahepatic biliary dilation
* **Blood cultures**: Positive for E. coli (sensitive to pip-tazo, ciprofloxacin)
* **Management**:
  + Piperacillin-tazobactam 4.5 g IV q6h × 7 days, then ciprofloxacin 500 mg PO BID × 3 days
  + ERCP with covered metal biliary stent (10 mm × 8 cm) placement (3/24/25)
  + Bile duct brushings: Negative for malignancy
* **Complications**:
  + A-fib with RVR (managed with metoprolol)
  + Hyperglycemia requiring insulin
  + AKI (Cr 1.8 → 1.3 mg/dL)

**3. Treatment History**

* **Chemotherapy**: FOLFIRINOX initiated 3/9/25
  + Cycle 2 postponed due to current infection
* **Prior procedures**:
  + ERCP with plastic stent (1/25/25)
  + EUS-guided FNA (2/10/25)

**4. Comorbidities**

* Rheumatoid arthritis (2010)
* COPD (GOLD Stage 2)
* Paroxysmal atrial fibrillation
* CAD (NSTEMI 2018)
* CKD Stage G3a (baseline eGFR 50-55)
* DM Type 2 (2025-01, likely secondary to pancreatic disease)
* Depression

**5. Discharge Medications**

* Ciprofloxacin 500 mg PO BID × 3 more days
* Oxycodone 5-10 mg PO q6h PRN
* Acetaminophen 650 mg PO q6h PRN
* Ondansetron 8 mg PO q8h PRN
* Metoprolol tartrate 50 mg PO BID
* Apixaban 5 mg PO BID
* Prednisone 5 mg PO daily
* Tiotropium inhaler 2 puffs daily
* Albuterol inhaler 2 puffs q4-6h PRN
* Insulin glargine 20 units SubQ at bedtime
* Insulin lispro sliding scale with meals
* Metformin 500 mg PO BID
* Sertraline 50 mg PO daily
* Pantoprazole 40 mg PO daily
* Creon 24,000 units: 2 capsules with meals, 1 with snacks

**6. Follow-up Plan**

* **Gastroenterology**: Dr. N. Rivera in 2 weeks (4/13/25)
  + Labs (CBC, CMP, lipase, amylase, PT/INR)
  + Stent removal/exchange in 3-6 months
  + RUQ ultrasound in 4 weeks
* **Oncology**: Dr. S. Chen in 2 weeks (4/13/25)
  + Tumor markers (CA 19-9, CEA)
  + Resume FOLFIRINOX cycle 2 ~4/15/25 with G-CSF support
* **Imaging**: Restaging CT chest/abdomen/pelvis 4/30/25
* **Primary Care**: Dr. T. Williams in 3 weeks (4/20/25)
* **Additional Services**:
  + Palliative care 4/15/25

**7. Lab Values (Admission → Discharge)**

* WBC: 18.6 → 8.4 × 10^9/L
* Hemoglobin: 10.2 → 10.5 g/dL
* Total Bilirubin: 12.4 → 4.2 mg/dL
* Direct Bilirubin: 9.6 → 3.1 mg/dL
* AST/ALT: 285/310 → 85/95 U/L
* Alkaline Phosphatase: 780 → 320 U/L
* Creatinine: 1.8 → 1.3 mg/dL
* eGFR: 37 → 53 mL/min/1.73m²
* Glucose: 238 → 156 mg/dL
* CRP: 15.6 → 3.2 mg/dL
* Blood cultures: E. coli → No growth

**Electronically Signed By**:  
Dr. N. Rivera (Gastroenterology) - 2025-03-30 15:30  
Dr. S. Chen (Medical Oncology) - 2025-03-30 14:15  
Dr. J. Wilson (Interventional Radiology) - 2025-03-30 13:45